Leuprolide

Overview

Leuprolide (also known as leuprorelin) is a synthetic nonapeptide analog of naturally occurring gonadotropin-releasing hormone (GnRH, also called LHRH). Developed in the late 1970s and first approved by the FDA in 1985, leuprolide has become one of the most widely used GnRH agonists in clinical medicine, with applications spanning oncology, reproductive endocrinology, and pediatric endocrinology.

The compound is marketed under several brand names corresponding to different formulations and delivery systems:

• Lupron Depot — intramuscular depot injection (monthly, 3-month, 4-month, and 6-month formulations)
• Eligard — subcutaneous depot using ATRIGEL delivery system (monthly, 3-month, 4-month, and 6-month)
• Fensolvi — subcutaneous depot for central precocious puberty (6-month formulation)
• Viadur (discontinued) — 12-month subcutaneous implant

The pharmacological principle underlying leuprolide's therapeutic utility is paradoxical: while GnRH agonists initially stimulate gonadotropin release, sustained continuous exposure desensitizes and downregulates GnRH receptors on pituitary gonadotrope cells. This results in a profound suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and consequently, a dramatic reduction in downstream sex hormone production — achieving what is often described as "medical castration" or "chemical castration" levels of testosterone or estrogen.

Structure and Sequence

Leuprolide is based on the decapeptide structure of native GnRH (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) with a single critical modification:

• Position 6: Glycine is replaced with D-leucine, and the C-terminal is modified to a propylamide (NHEt) instead of Gly-NH2

Sequence: pGlu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt

• Molecular formula: C59H84N16O12
• Molecular weight: approximately 1,209.4 g/mol
• Key structural features: The D-amino acid substitution at position 6 confers resistance to enzymatic degradation and increases binding affinity for the GnRH receptor approximately 15- to 80-fold compared to native GnRH

Mechanism of Action

Biphasic Response

Leuprolide's mechanism involves a characteristic biphasic hormonal response:

Initial stimulation phase (first 1-2 weeks, "flare"):

• Leuprolide binds to and activates GnRH receptors on anterior pituitary gonadotropes
• This triggers an initial surge in LH and FSH release
• Consequently, sex hormone levels transiently increase (testosterone in males, estradiol in females)
• This flare can temporarily worsen hormone-sensitive conditions (e.g., bone pain in prostate cancer)
• Anti-androgens (e.g., bicalutamide, flutamide) are often co-administered during this phase in prostate cancer to mitigate flare effects

Sustained suppression phase (after 2-4 weeks):

• Continuous, non-pulsatile GnRH receptor stimulation causes receptor desensitization and internalization
• GnRH receptor density on gonadotropes decreases markedly (downregulation)
• LH and FSH secretion falls to castrate levels
• In males: testosterone declines to below 50 ng/dL (often below 20 ng/dL)
• In females: estradiol declines to postmenopausal levels (below 20 pg/mL)
• Spermatogenesis and ovarian follicular development cease

This biphasic mechanism distinguishes GnRH agonists from GnRH antagonists (e.g., degarelix), which achieve immediate suppression without an initial flare.

Downstream Effects

The suppression of sex hormones produces tissue-specific consequences depending on the clinical context:

• Prostate tissue: Androgen deprivation leads to apoptosis of androgen-dependent prostate cancer cells
• Endometrial tissue: Estrogen deprivation causes atrophy of ectopic endometrial implants
• Uterine tissue: Reduction in myoma (fibroid) volume by 30-65%
• Hypothalamic-pituitary-gonadal axis: Complete functional suppression during treatment, typically reversible upon discontinuation

Research Summary

Pharmacokinetics

• Bioavailability (subcutaneous): approximately 90%
• Depot formulations: Sustained release over 1, 3, 4, or 6 months depending on formulation
• Half-life: approximately 3 hours (after subcutaneous bolus injection)
• Depot duration: microsphere and polymer matrix formulations maintain therapeutic levels for the labeled duration
• Metabolism: degradation by peptidases; no significant hepatic CYP involvement
• Protein binding: approximately 43-49%
• Testosterone suppression onset: castrate levels typically achieved within 2-4 weeks of depot initiation
• Recovery after discontinuation: testosterone recovery to baseline typically occurs within 4-24 weeks, depending on treatment duration; prolonged suppression reported in some cases

Common Discussion Topics

Testosterone Flare and Clinical Management

The initial testosterone surge during the first 1-2 weeks of leuprolide therapy is a significant clinical consideration in prostate cancer. Patients with high-volume metastatic disease, particularly those with spinal cord compression or ureteral obstruction, may experience dangerous disease flare. Standard practice involves concurrent anti-androgen administration (flutamide or bicalutamide) for the first 2-4 weeks to block the effects of the testosterone surge at the receptor level.

Bone Mineral Density Loss

Prolonged sex hormone suppression with leuprolide therapy is associated with significant bone mineral density loss, increasing fracture risk. In prostate cancer patients on long-term androgen deprivation, annual bone density loss of 2-4% has been documented. Strategies discussed include concurrent bisphosphonate or denosumab therapy, weight-bearing exercise, calcium and vitamin D supplementation, and periodic bone density monitoring.

Metabolic Consequences of Androgen Deprivation

Long-term leuprolide use in men is associated with metabolic syndrome features including increased body fat, insulin resistance, dyslipidemia, and potentially increased cardiovascular risk. These effects have prompted discussion about intermittent versus continuous androgen deprivation strategies in prostate cancer, and about metabolic monitoring during treatment.

Use in Transgender Medicine

Leuprolide is used as a puberty-suppressing agent in gender-dysphoric adolescents, allowing time for psychosocial assessment before irreversible interventions. The effects are considered reversible upon discontinuation. This application has generated substantial public discourse regarding appropriate age of initiation, long-term safety data in this population, and the intersection of medical evidence with policy considerations.

Comparison with GnRH Antagonists

GnRH antagonists such as degarelix and the oral agent relugolix achieve gonadotropin suppression without the initial flare phase. Relugolix in particular has demonstrated a potentially superior cardiovascular safety profile compared to leuprolide in the HERO trial. Discussion continues regarding whether GnRH antagonists should replace agonists as the standard of care for prostate cancer androgen deprivation.

Dosing Protocols

The following dosing information reflects FDA-approved clinical guidelines. Leuprolide is available in multiple depot formulations. Always consult a qualified healthcare professional.

Flare management (prostate cancer): Co-administer an anti-androgen (bicalutamide or flutamide) beginning 1-2 weeks before and continuing for 2-4 weeks after the first leuprolide injection to mitigate testosterone flare effects.

Related Compounds

• Triptorelin — Another GnRH agonist with similar mechanism and indications, differing in formulation and pharmacokinetic profile
• Nafarelin — A GnRH agonist administered as a nasal spray, primarily used for endometriosis and precocious puberty
• Macimorelin — An oral growth hormone secretagogue used in endocrine diagnostics, relevant to broader peptide hormone pharmacology